

U.S.S.N.: 08/488,097

Filed: June 7, 1995

AMENDMENT AND RESPONSE TO OFFICE ACTION

C2 wherein R₁ [and R₂ are] is selected from the group consisting of [acetic, propionic, butyric, and pentanoic or R₁ can be a mono, di or triphosphate ester, and one of R₁ or R₂ can be hydrogen] hydrogen, acetyl, propionyl, butyryl, and pentanoyl and R₂ is hydrogen.

Sub D² C3 8. β -2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, or its mono, di, or triphosphate ester.

C4 3/11. (Amended) The compound of claim 5, wherein R₁ is [butyric] butyryl and R₂ is hydrogen.

4/12. A physiologically acceptable salt of β -2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane.

[Please add the following claims.

C5 5/37. A pharmaceutical composition comprising an effective amount to treat HIV in humans of a physiologically acceptable salt of β -2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane.

6/38. A pharmaceutical composition comprising an effective amount to treat HIV in humans of the mono-, di- or triphosphate ester of β -2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane.